Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.46 |
| ▸ | AGBL2 | Q5U5Z8 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.37 |
| ▸ | NPC1 | O15118 | 2/20 | 0.37 |
| ▸ | RAB9A | P51151 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 4/20 | 0.36 |
| ▸ | GFER | P55789 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | HMGCR | P04035 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.34 |
| ▸ | EGFR | P00533 | 1/20 | 0.34 |
| ▸ | GLA | P06280 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | PTGES | O14684 | 1/20 | 0.33 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.33 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30745351 | 1.00 | HSP90AB1 (0.46) | HSP90AB1AGBL2ALDH1A1NPC1RAB9A | |
| SCHEMBL21801325 | 0.85 | AGBL2 (0.49) | HSP90AB1AGBL2ALDH1A1NPC1RAB9A | |
| SCHEMBL27462821 | 0.84 | DPP4 (0.43) | AGBL2ALDH1A1SMN1; SMN2KDM4ESYK | |
| SCHEMBL23273501 | 0.83 | HSP90AB1 (0.38) | HSP90AB1AGBL2ALDH1A1NPC1RAB9A | |
| SCHEMBL29737883 | 0.83 | HSP90AB1 (0.38) | HSP90AB1AGBL2ALDH1A1NPC1RAB9A | |
| Hydrochloric Acid SCHEMBL31147900 | 0.81 | HSP90AB1 (0.37) | HSP90AB1AGBL2ALDH1A1NPC1RAB9A | |
| SCHEMBL14683566 | 0.81 | HTT (0.41) | ALDH1A1RAB9ASMN1; SMN2MAPTKDM4E | |
| SCHEMBL4166504 | 0.81 | HSP90AB1 (0.46) | HSP90AB1ALDH1A1NPC1RAB9AGAA | |
| SCHEMBL14677552 | 0.80 | P4HTM (0.46) | ALDH1A1NPC1RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL30745360 | 0.80 | P4HTM (0.46) | ALDH1A1NPC1RAB9ASMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4334304-A1 | BENZIMIDAZOYL GLP-1 RECEPTOR AGONISTS, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME, AND METHODS FOR THEIR USE | Carmot Therapeutics, Inc. (US) | 2024-03-13 | — | — | EP | disclosed |
| US-20220396569-A1 | BENZIMIDAZOYL GLP-1 RECEPTOR AGONISTS, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME, AND METHODS FOR THEIR USE | CARMOT THERAPEUTICS, INC. | 2022-12-15 | — | — | US | disclosed |
| WO-2022235717-A1 | BENZIMIDAZOYL GLP-1 RECEPTOR AGONISTS, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME, AND METHODS FOR THEIR USE | CARMOT THERAPEUTICS, INC. (US) | 2022-11-10 | — | — | WO | disclosed |
| US-20140155381-A1 | COMPOUNDS AND METHODS | TEMPERO PHARMACEUTICALS, INC. | 2014-06-05 | — | — | US | disclosed |
| US-20140155381-A1 | COMPOUNDS AND METHODS | TEMPERO PHARMACEUTICALS, INC. | 2014-06-05 | — | — | US | disclosed |
| US-20140155381-A1 | COMPOUNDS AND METHODS | TEMPERO PHARMACEUTICALS, INC. | 2014-06-05 | — | — | US | disclosed |
| EP-2736332-A1 | COMPOUNDS AND METHODS | Tempero Pharmaceuticals, Inc. (US) | 2014-06-04 | — | — | EP | disclosed |
| WO-2013019653-A1 | COMPOUNDS AND METHODS | TEMPERO PHARMACEUTICALS, INC. (US) | 2013-02-07 | — | — | WO | disclosed |
| WO-2013019653-A1 | COMPOUNDS AND METHODS | TEMPERO PHARMACEUTICALS, INC. (US) | 2013-02-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140155381-A1 | COMPOUNDS AND METHODS | RORC, RORB, RORA | HSP90AB1 1155/4885AGBL2 2554/4885ALDH1A1 820/4885 |
| US-20220396569-A1 | BENZIMIDAZOYL GLP-1 RECEPTOR AGONISTS, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME, AND METHODS FOR THEIR USE | GLP1R, GIPR, GCGR | HSP90AB1 1255/4885AGBL2 2919/4885ALDH1A1 3087/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.